Article information
Resumen
Objetivo
Revisar los efectos de la terapia hormonal sustitutiva, en sus distintas formas, en el metabolismo lipídico
FuentesBibliografía médica hasta septiembre del año 2000 a través de MEDLINE
ConclusionesLos estrógenos, combinados o no con progestágenos, inducen un perfil lipoproteico favorable. Buena parte de esa acción se ejerce a través de modificación en la cinética de partículas. Las acciones sobre oxidación de las lipoproteínas de baja densidad (LDL), o el tamaño de sus partículas, son motivo de polémica. Nuevos preparados, con capacidad de activar receptores estrogénicos, también demuestran ejercer acciones selectivas sobre el metabolismo lipídico
Palabras clave:
Enfermedad cardiovascular
Hormonas
LDL oxidada
Tamaño de LDL
Menopausia
Objective
To review the effects of the distinct forms of hormone replacement therapy on lipid metabolism
Data sourcesThe medical literature up to September 2000, reviewed through Medline
ConclusionsEstrogens, alone or combined with progestagens, induce a favorable lipoprotein profile. A major part of that action is exerted through modification in the kinetics of particles. The actions on LDL oxidation, or on the size of its particles, are debatable. New compounds, able to activate estrogen receptors, also demonstrate selective actions on lipid metabolism
Keywords:
Cardiovascular disease
Hormones
Oxidized LDL
LDL size
Menopause
Full text is only aviable in PDF
Bibliografía
[1.]
R.K. Ross, A. Paganini-Hill, T.M. Mack, M. Arthur, B.E. Henderson.
Menopausal oestrogen therapy and protection from death from ischaemic heart disease.
Lancet, 1 (1981), pp. 858-860
[2.]
M.S. Moskowitz, A.A. Moskowitz, W. Bradford.
Changes in serum lipids and coronary arteries of the rat in response to estrogen.
Arch Pathol, 61 (1956), pp. 245-263
[3.]
The Writing Group for the PEPI Trial.
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.
Jama, 273 (1995), pp. 199-208
[4.]
K. Nakai, C. Itoh, K. Hotta, T. Itoh, M. Yoshizumi, K. Hiramori.
Estradiol-17 beta regulates de induction of VCAM-1 mRNA expression by interleukin-1 beta in human umbilical vein endothelial cells.
Life Sci, 54 (1994), pp. 221-227
[5.]
A.N. MacRitchie, S.S. Jun, Z. Chen, Z. German, I.S. Yuhanna, T.S. Sherman, et al.
Estrogen upregulates endothelial nitric oxide synthase gene expression in fetal pulmonary artery endothelium.
Circ Res, 81 (1997), pp. 355-362
[6.]
B.W. Walsh, I. Schiff, B. Rosner, L. Greenberg, V. Ravnikar, F.M. Sacks.
Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.
N Engl J Med, 325 (1991), pp. 1196-1204
[7.]
A. Wakatsuki, Y. Sagara.
Lipoprotein metabolism in postmenopausal and oophorectomized women.
Obstet Gynecol, 85 (1995), pp. 523-528
[8.]
A. Karjalainen, J. Heikkinen, M.J. Savolainen, A.C. Backstrom, Y.A. Kesaniemi.
Mechanisms regulating LDL metabolism in subjects on peroral and transdermal estrogen replacement therapy.
Arterioscler Thromb Vasc Biol, 20 (2000), pp. 1101-1106
[9.]
K.A. Matthews, E. Meilahn, L.H. Kuller, S.F. Kelsey, A.W. Caggiula, R.R. Wing.
Menopause and risk factors for coronary heart disease.
N Engl J Med, 321 (1989), pp. 641-646
[10.]
R.M. Krauss.
Lipids and lipoproteins and effects of hormone replacement.
Treatment of the postmenopausal woman. Basic and clinical aspects, 2.a ed, pp. 369-376
[11.]
M. Navab, S.S. Imes, S.Y. Hama, G.P. Hough, L.A. Ross, R.W. Bork, et al.
Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein.
J Clin Invest, 88 (1991), pp. 2039-2046
[12.]
K. Sugioka, Y. Shimosegawa, M. Nakano.
Estrogens as natural antioxidants of membrane phospholipid peroxidation.
FEBS Lett, 210 (1987), pp. 37-39
[13.]
C. Maziere, M. Auclair, M. Ronveaux, S. Salmon, R. Santus, J.C. Maziere.
Estrogen inhibits copper and cell-mediated modification of low density lipoprotein.
Atherosclerosis, 89 (1991), pp. 175-182
[14.]
V.A. Rifici, A.K. Khachadurian.
The inhibition of low density lipoprotein oxidation by 17-beta estradiol.
Metabolism, 41 (1992), pp. 1110-1114
[15.]
H. Seeger, A.O. Mueck, T.H. Lippert.
The inhibitory effect of endogenous estrogen metabolites on copper-mediated in vitro oxidation of LDL.
Int J Clin Pharmacol Ther, 36 (1998), pp. 383-385
[16.]
N. Santanam, R. Shern-Brewer, R. McClactey, P.Z. Castellano, A.A. Murphy, S. Voelkel, et al.
Estradiol as an antioxidant: incompatible with its physiological concentrations and function.
J Lipid Res, 39 (1998), pp. 2111-2118
[17.]
R. Dittrich, A. Muller, J. Hensen, L. Wildt.
The inhibition of low density lipoprotein oxidation by 17-alpha estradiol.
Exp Clin Endocrinol Diabetes, 107 (1999), pp. 53-57
[18.]
A. Wakatsuki, N. Ikenoue, Y. Sagara.
Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women.
Maturitas, 28 (1998), pp. 229-234
[19.]
J. McManus, J. McEneny, W. Thompson, I.S. Young.
The effect of hormone replacement therapy on the oxidation of low density lipoprotein in postmenopausal women.
Atherosclerosis, 135 (1997), pp. 73-81
[20.]
N. Hoogerbrugge, M.C. Zillikens, H. Jansen, K. Meeter, J.W. Deckers, J.C. Birkenhäger.
Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease.
Metabolism, 47 (1998), pp. 675-680
[21.]
A.M. Heikkinen, S.I.N. Niskanen, S. Ylä-Herttuala, J. Luoma, M.T. Tuppurainen, M. Komulainen, et al.
Postmenopausal hormone replacement therapy and autoantibodies against oxidized LDL.
Maturitas, 29 (1998), pp. 155-161
[22.]
D.V. Parums, D.L. Brown, M.J. Mitchinson.
Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis.
Arch Pathol Lab Med, 114 (1990), pp. 383-387
[23.]
V.W. Armstrong, E. Wieland, F. Diedrich, A. Renner, W. Rath, H. Kreuzer, et al.
Serum antibodies to oxidized low-density lipoprotein in pre-eclamptic and coronary disease.
Lancet, 343 (1994), pp. 1570-1571
[24.]
M. Schumacher, B. Eber, F. Tatzber, P. Kaufmann, H. Esterbauer, W. Klein.
LDL oxidation and coronary atherosclerosis.
Lancet, 340 (1992), pp. 123
[25.]
B. Eber, M. Schumacher, F. Tatzber, P. Kaufmann, O. Luha, H. Esterbauer, et al.
Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty.
Cardiology, 84 (1994), pp. 310-315
[26.]
H. Campos, J.R. McNamara, P.W. Wilson, J.M. Ordovas, E.J. Schaefer.
Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women.
J Clin Endocrinol Metab, 67 (1988), pp. 30-35
[27.]
A.R. Roscini, G. Lupattelli, D. Siepi, S. Pagliaricci, M. Pirro, E. Mannarino.
Low-density lipoprotein size in primary hypothyroidism. Effects of hormone replacement therapy.
Ann Nutr Metab, 43 (1999), pp. 374-379
[28.]
A. Granfone, H. Campos, J.R. McNamara, M.M. Schaefer, S. Lamon- Fava, J.M. Ordovas, et al.
Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopusal, dyslipidemic women.
Metabolism, 41 (1992), pp. 1193-1198
[29.]
H. Campos, F.M. Sacks, B.W. Walsh, Y. Schiff, M.A. O'Hanesian, R.M. Krauss.
Differential effects of estrogen on low-density lipoprotein subclasses in healthy postmenopausal women.
Metabolism, 42 (1993), pp. 1153-1158
[30.]
B. Griffin, E. Farish, D. Walsh, J. Barnes, M. Caslake, J. Shepherd, et al.
Response of plasma low-density lipoprotein subfractions to oestrogen replacement therapy following surgical menopause.
Clin Endocrinol, 39 (1993), pp. 463-468
[31.]
M.J. Van der Mooren, J. De Graaf, P.N.M. Demacker, A.F.J. De Haan, R. Rolland.
Changes in the low-density lipoprotein profile during 17beta-estradiol-dydrogesterone therapy in postmenopausal women.
Metabolism, 43 (1994), pp. 799-802
[32.]
M. Tilly-Kiesi, M. Lappi, J. Puolakka, H. Luotola, T. Pyorala, M.R. Taskinen.
Different effects of continuos oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses.
Eur J Clin Invest, 26 (1996), pp. 1125-1133
[33.]
A. Wakatsuki, N. Ikenoue, Y. Sagara.
Estrogen-induced small low-density lipoprotein particles in postmenopausal women.
Obstet Gynecol, 91 (1998), pp. 234-240
[34.]
K.A. McKinney, P.B. Duell, D.L. Wheaton, D.L. Hess, P.E. Patton, H.G. Spies, et al.
Differential effects of subcutaneous estrogen and progesterone on low-density lipoprotein size and susceptibility to oxidation in postmenopausal rhesus monkeys.
Fertil Steril, 68 (1997), pp. 525-530
[35.]
H. Campos, B.W. Walsh, H. Judge, F.M. Sacks.
Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women.
J Clin Endocrinol Metab, 82 (1997), pp. 3955-3963
[36.]
R.A. Srivastava, D. Baumann, G. Schonfeld.
In vivo regulation of low density-lipoprotein receptors by estrogens differs at the post-transcriptional level in rat and mouse.
Eur J Biochem, 216 (1993), pp. 527-538
[37.]
J. Jensen, B.J. Riis, V. Strom, L. Nilas, C. Christiansen.
Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women.
Am J Obstet Gynecol, 156 (1987), pp. 66-71
[38.]
M.J. Tikkanen, E.A. Nikkila, T. Kuusi, S.U. Sipinen.
High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and Norgestrel.
J Clin Endocrinol Metab, 54 (1982), pp. 1113-1117
[39.]
V.T. Miller, R.A. Muesing, J.C. LaRosa, D.B. Stoy, E.A. Phillips, R.J. Stillman.
Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-density lipoprotein subfractions, and apolipoprotein A-I.
Obstet Gynecol, 77 (1991), pp. 235-240
[40.]
A. Cano, H. Fernandes, S. Serrano, P. Mahiques.
Effect of continuous oestradiol-medroxiprogesterone administration on plasma lipids and lipoproteins.
Maturitas, 13 (1991), pp. 35-42
[41.]
B.M. Wolfe, M.W. Huff.
Effects of combined estrogen and progestin administration on plasma lipoprotein metabolism in postmenopausal women.
J Clin Invest, 83 (1989), pp. 40-45
[42.]
A.O. Mueck, H. Seeger, T.H. Lippert.
Estradiol inhibits LDL oxidation: do the progestins medroxyprogesterone acetate and norethisterone acetate influence this effect?.
Clin Exp Obstet Gynecol, 25 (1998), pp. 26-28
[43.]
J. Schröder, M. Dören, B. Scheneider, M. Oettel.
Are the antioxidative effects of 17b-estradiol modified by concomitant administration of a progestin?.
Maturitas, 25 (1996), pp. 133-139
[44.]
E. Arteaga, A. Rojas, P. Villaseca, M. Bianchi, A. Arteaga, D. Duran.
In vitro effect of estradiol, progesterone, testosterone, and of combined estradiol/progestins on low density lipoprotein (LDL) oxidation in postmenopausal women.
Menopause, 5 (1998), pp. 16-23
[45.]
X. Zhu, B. Bonet, R.H. Knopp.
Estradiol 17beta inhibition of LDL oxidation and endothelial cell cytotoxicity is opposed by progestins to different degrees.
Atherosclerosis, 148 (2000), pp. 31-41
[46.]
V. Mijatovic, P. Kenemans, J.C. Netelenbos, E.R. Peters-Muller, G.J. Van Kamp, G.A. Voetberg, et al.
Oral 17 b-estradiol continuously combined with dydrogesterone lowers serum lipoprotein(a) concentrations in healthy postmenopausal women.
J Clin Endocrinol Metab, 82 (1997), pp. 3543-3547
[47.]
M.J. Van der Mooren, P.N.M. Demacker, H.J. Blom, Y.B. De Rijke, R. Rolland.
The effect of sequential three-monthly hormone replacement therapy on several cardiovascular risk estimators in postmenopausal women.
Fertil Steril, 67 (1997), pp. 67-73
[48.]
C.C. McDonald, H.J. Stewart.
Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.
Br Med J, 303 (1991), pp. 435-437
[49.]
L.E. Rutqvist, A. Mattsson.
Cardiac and thromboembolic morbidity among postmenopausal women with early stage breast cancer in a randomized trial of adjuvant tamoxifen.
J Natl Cancer Inst, 85 (1993), pp. 1398-1406
[50.]
V. Guetta, R.M. Lush, W.D. Figg, M.A. Waclawiw, S. Cannon RO.
Effect of the antiestrogen tamoxifen on low-density lipoprotein concentration and oxidation in postmenopausal women.
Am J Cardiol, 76 (1995), pp. 1072-1073
[51.]
B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, et al.
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst, 90 (1998), pp. 1371-1388
[52.]
P.D. Delmas, N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, et al.
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
N Engl J Med, 337 (1997), pp. 1641-1647
[53.]
B.W. Walsh, L.H. Kuller, R.A. Wild, S. Paul, M. Farmer, J.B. Lawrence, et al.
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Jama, 279 (1998), pp. 1445-1451
[54.]
S.H. Zuckerman, N. Bryan.
Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene.
Atherosclerosis, 126 (1996), pp. 65-75
[55.]
J.W. Anderson, B.M. Johnstone, M.E. Cook-newell.
Meta-analisis of effects of soy protein intake on serum lipids.
N Engl J Med, 333 (1995), pp. 276-282
[56.]
M.W. Huff, D.C.K. Roberts, K.K. Caroll.
Long-term effects of semipurified diets containing casein or soy protein isolate on atherosclerosis and plasma lipoproteins in rabbits.
Atherosclerosis, 41 (1982), pp. 327-336
[57.]
M.S. Anthony, T.B. Clarkson, C.L. Hughes.
Plant and mamalian estrogen effects on plasme lipids on female monkeys.
Circulation, 90 (1994), pp. 1-235
[58.]
M.B. Ruiz-Larrea, A.R. Mohan, G. Paganga, N.J. Miller, G.P. Bolwell, C.A. Rice-Evans.
Antioxidant activity of phytoestogenic isoflavones.
Free Rad Res, 26 (1997), pp. 63-70
[59.]
T.B. Clarckson, M.S. Anthony.
Phytoestrogens and coronary heart disease.
Bailière's Clin Endocrinol Metab, 12 (1998), pp. 589-604
[60.]
E.K. Honore, J.K. Williams, M.S. Anthony, T.B. Clarkson.
Soy isoflavones enhance vascular reactivity in atherosclerotic female macaques.
Fertil Steril, 67 (1997), pp. 148-154
[61.]
S.M. Potter, J.A. Baum, H. Teng, R.J. Stillman, N.F. Shay, J.r. Erdman JW.
Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women.
Am J Clin Nutr, 68 (1998), pp. 1375-1379
[62.]
S. Washburn, G.L. Burke, T. Morgan, M. Anthony.
Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptons in perimenopausal women.
Menopause, 6 (1999), pp. 7-13
[63.]
J.M. Hodgson, I.B. Puddey, L.J. Beilin, T.A. Mori, K.D. Croft.
Supplemetation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans.
J Nutr, 128 (1998), pp. 728-732
[64.]
P.J. Nestel, S. Pomeroy, S. Kay, P. Komesaroff, J. Behrsing, J.D. Cameron, et al.
Isoflavones from Red Clover improve systemic arterial compliance but not plasma lipids in menopausal women.
J Clin Endocinol Metab, 84 (1999), pp. 895-898
Copyright © 2001. Sociedad Española de Ginecología y Obstetricia